Keratoacanthoma News and Research

RSS
GSK reports 45% survival rate in phase III study of Tafinlar in BRAF V600E mutant metastatic melanoma

GSK reports 45% survival rate in phase III study of Tafinlar in BRAF V600E mutant metastatic melanoma

Dabrafenib shows significant anti-tumour activity in BRAF V600E mutant non-small cell lung cancer

Dabrafenib shows significant anti-tumour activity in BRAF V600E mutant non-small cell lung cancer

PLX4032 therapy results in tumor shrinkage in metastatic melanoma patients

PLX4032 therapy results in tumor shrinkage in metastatic melanoma patients

Plexxikon announces Phase 1 extension study results of PLX4032 in metastatic colorectal cancer

Plexxikon announces Phase 1 extension study results of PLX4032 in metastatic colorectal cancer

Plexxikon commences patient dosage in PLX4032 trials for metastatic melanoma

Plexxikon commences patient dosage in PLX4032 trials for metastatic melanoma

Phase 1 extension study results of Plexxikon's PLX4032 in metastatic melanoma patients encouraging

Phase 1 extension study results of Plexxikon's PLX4032 in metastatic melanoma patients encouraging